4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
US-9290504-B2 · Mar 22, 2016 · US
4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
US9758524B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758524-B2 |
| Application number | US-201615019543-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 9, 2016 |
| Priority date | Jul 19, 2011 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating Mantle Cell Lymphoma (MCL) in a human subject, the method comprising administering to the human subject a compound which is (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, having the structure: or a pharmaceutically acceptable salt thereof, in an amount effective to treat the MCL in the human subject. 2. The method of claim 1 , wherein the compound is present in a pharmaceutical composition. 3. The method of claim 2 , wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable auxiliaries. 4. The method of claim 2 , wherein the pharmaceutical composition is administered to the human subject by oral administration. 5. The method of claim 3 , wherein the pharmaceutical composition is administered to the human subject by oral administration. 6. The method of claim 4 , wherein the pharmaceutical composition is a tablet. 7. The method of claim 5 , wherein the pharmaceutical composition is a tablet. 8. The method of claim 4 , wherein the pharmaceutical composition is a capsule. 9. The method of claim 5 , wherein the pharmaceutical composition is a capsule. 10. The method of claim 4 , wherein the pharmaceutical composition is a suspension. 11. The method of claim 5 , wherein the pharmaceutical composition is a suspension. 12. The method of claim 1 , wherein the amount administered to the human subject is 0.0001-25 mg per kg body weight. 13. The method of claim 1 , wherein the compound (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject. 14. The method of claim 1 , wherein a pharmaceutically acceptable salt of the compound (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject.
Assignees
Inventors
Classifications
Drugs for disorders of the blood or the extracellular fluid · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9758524B2 cover?
- The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the…
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).